How many times should I follow up with a CTO (after a demo)?

If they agreed in principle, send times the same day while intent is warm. Same day with the recap. A value bump 3 days later if they went quiet. After that, send a breakup note and archive it. A CTO who wants it will answer a clean close more often than a fifth bump.

Is it rude to send a calendar link?

It's rude when the link is the whole email. It's fine when you include an agenda, two suggested times, and a note that they can pick anything else. Give them a way to stay in the thread. Name the stall they care about, offer one small next step, and stop before the thread feels like a sequence.

Should I include a recording in the demo follow-up?

If you recorded it and they agreed, yes, plus timestamps for the two parts they cared about. A raw 40-minute link with no map is homework. Add the three bullets they'd need to brief a colleague. Name the stall they care about, offer one small next step, and stop before the thread feels like a sequence.

Is it okay to send this meeting request on LinkedIn instead of email?

Yes if this CTO is actually active there and the thread isn't about long attachments. Keep the LinkedIn version even shorter. Don't paste the full email. One context line and one question is plenty. Name the stall they care about, offer one small next step, and stop before the thread feels like a sequence.

What should I never say in a Pharmaceuticals meeting request?

Don't use consumer-startup slang. It's a credibility leak. Calling it 'AI-powered' with no description of the system. Don't send a 19-page deck that relitigates features they skipped. Those three mistakes show up constantly in Pharmaceuticals inboxes and they all read as "this was templated."

Pharmaceuticals · CTO · After Demo

Meeting Request for Pharmaceuticals CTO: After Demo

When a Pharmaceuticals CTO goes quiet (after a demo), the right meeting request email does one job: make a reply cheaper than silence. They look for architecture, failure modes, and whether you'll create toil for their team. Fluff is a ranking signal that you don't know the work. That's why this template leads with time through MLR, access, and compliant

Last updated: 2026-09-02 · Reviewed by: Sales Email Template editors

We write templates the way we wrote emails on quota: short, specific, and easy to forward. When we cite research below, it is because the number changes how a buyer reads your note, not to pad the page.

Sources: HubSpot sales email benchmarks; Gong follow-up research

Why does this meeting request work for a Pharmaceuticals CTO?

Offer two times plus an async escape hatch.
Speaks to follow-up that ignores MLR, off-label risk, and the fact that 'just a quick claim' isn't quick instead of a generic "value prop."
Fits how a CTO actually reads: 90 words is plenty if the substance is real. Don't pad.
Replay the two moments they leaned in, and the one concern they named.
Promise notes so the meeting has a paper trail.

When should I send this to a Pharmaceuticals CTO?

If they agreed in principle, send times the same day while intent is warm. Same day with the recap. A value bump 3 days later if they went quiet. For this combo, treat "Same day, then 3 days if silent" as the default, then adjust around launch calendars and review boards set speed. you don't. If you're emailing a CTO, 90 words is plenty if the substance is real. Don't pad.

What this CTO actually cares about

A CTO in Pharmaceuticals is protecting reliability, security, and engineering time. They look for architecture, failure modes, and whether you'll create toil for their team. Fluff is a ranking signal that you don't know the work. The hook that earns a look is an incident class, a security gap, or a cost line they already hate. The ask should stay at this size: a technical working session or a written teardown, not a 'vision call'. Delete trigger: Calling it 'AI-powered' with no description of the system. If your note would embarrass them in a team channel, rewrite it.

How Pharmaceuticals changes the note

Pharmaceuticals buyers are commercial, medical, and ops leads who work under review boards and long timelines. Don't invent clinical claims. Don't treat HCPs like a funnel. If you don't know the rules, your email is a liability. A credible proof point in this vertical sounds like: cut review cycles on a leave-behind by catching claims issues before legal saw the tenth draft. Watch the language. Words that land here include MLR, label, access, HCP, congress, promotional review. Buyers here measure success with time through MLR, access, and compliant engagement rates. Buyers here measure success with time through MLR, access, and compliant engagement rates.

How should I customize this template before I send it?

Replace the pain line with an agency waiting on MLR while the sales team keeps asking 'is it approved yet'.
Keep the tone precise.
If they prefer email, don't keep pushing Zoom.
Time it for Same day, then 3 days if silent. Same day with the recap. A value bump 3 days later if they went quiet.
Don't use consumer-startup slang. It's a credibility leak.

What mistakes should I avoid with this after demo note?

Calendly links with no agenda look like a trap.
Don't send a 19-page deck that relitigates features they skipped.
Don't use consumer-startup slang. It's a credibility leak.
Calling it 'AI-powered' with no description of the system.

How does this after demo scenario compare?

Dimension	For this template
Best send window	Same day, then 3 days if silent
Ideal length	90 words is plenty if the substance is real. Don't pad.
Primary ask	a technical working session or a written teardown, not a 'vision call'
Industry metric to cite	time through MLR, access, and compliant engagement rates
Tone	Precise. No slogans. It's fine to be a little dry.
Unlike after meeting	They have product context now. Speak to what they saw, not to a generic intro.
Unlike after proposal	Pricing may not be on paper yet. Don't jump to 'ready to sign.'

What should I copy and send?

Copy-ready template

Subject

Pharmaceuticals note on follow-up that ignores MLR, off-label risk,

Body

Hi [First Name],

This isn't a pitch dump. I want to walk through [one decision].

In Pharmaceuticals, that usually shows up as follow-up that ignores MLR, off-label risk, and the fact that 'just a quick claim' isn't quick. Agenda: 5 minutes on current [process], 5 on where [Your Product] would sit, 5 on go / no-go. I'll send notes after either way.

Replay the two moments they leaned in, and the one concern they named.

Prefer async? I'll send the brief today.

Best,
[Your Name]
[Your Title]
[Your Company]

Questions people ask before they hit send

Name the situation and the business object, not your excitement. Something like "Pharmaceuticals note on follow-up that ignores MLR, off-label risk," outperforms "Just checking in" because a CTO can decide from the preview text whether it's worth opening. Keep it under 50 characters when you can.

Related templates

Want a custom draft instead? Try the email generator.